Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Sigma-Aldrich

- PMLiVE

Actavis claims top UK generics spot with Auden Mckenzie buy

Firm claims the deal will make it the UK’s third-largest pharma manufacturer

Roche Basel Switzerland

Roche buys rare disease firm Trophos in €470m deal

Will take control of olesoxime for spinal muscular atrophy

Shire Basingstoke

Shire signs deal to buy NPS for $5.2bn

Firm hopes to boost its presence in rare disease sector

- PMLiVE

Merck stumps up $375m for cancer firm OncoEthix

Follows $8.4bn deal to buy Cubist

- PMLiVE

UCB’s $1.53bn generics sale falls through

Advent and Avista Capita back away from bid to acquire Kremers Urban due to unanticipated conflict in timing

- PMLiVE

Merck: You need to win locally in consumer health

And company says it would consider targeted 'bolt-on' acquisitions

- PMLiVE

AZ says cancer will be ‘sixth growth platform’

Firm currently has 14 drugs in phase III trials

- PMLiVE

Pfizer signs $2.85bn immuno-oncology alliance

Will jointly develop Merck KGaA's lead anti-PD-L1 drug

Merck KGaA’s Oschmann elected president of IFPMA

He takes over from Lilly’s John Lechleiter

Bristol-Myers Squibb (BMS) building

BMS takes option to buy fibrosis firm Galecto

The Swedish biotech has a pulmonary fibrosis candidate in early-stage testing

- PMLiVE

AbbVie is not looking at another big acquisition, says CEO

Unlikely to consider another deal on the scale of failed Shire merger

Bristol-Myers Squibb (BMS) building

BMS taps F-star Alpha for immuno-oncology drug

Drug in development for breast and stomach cancers

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links